Long‐term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease

An open‐label, long‐term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL‐M/CLD 20/12.5 mg (n = 77) or OLM/HCTZ 20/12.5 mg...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Hypertens (Greenwich)
Hoofdauteurs: Bakris, George L., Zhao, Lin, Kupfer, Stuart, Juhasz, Attila, Hisada, Michie, Lloyd, Eric, Oparil, Suzanne
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2018
Onderwerpen:
Hypertension Therapy
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8031057/
https://ncbi.nlm.nih.gov/pubmed/29504252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.13230
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items